Rankings
▼
Calendar
CTNM Q3 2023 Earnings — Contineum Therapeutics, Inc. Class A Common Stock Revenue & Financial Results | Market Cap Arena
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
$504M
Q3 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$8M
Net Income
-$6M
EPS (Diluted)
$-0.25
QoQ Revenue Growth
-100.0%
Cash Flow
Operating Cash Flow
-$5M
Free Cash Flow
-$5M
Stock-Based Comp.
$477,000
Balance Sheet
Total Assets
$139M
Total Liabilities
$200M
Stockholders' Equity
-$61M
Cash & Equivalents
$18M
← FY 2023
All Quarters
Q4 2023 →
